Episurf Medical AB

Episurf Medical AB. Episurf Medical AB is a Sweden-based medical technology company. It is engaged in the development, manufacture and marketing of implants and surgical drilling templates used in the treatment of local cartilage damage in knee joints. The Company's product portfolio includes the Episealer, and individually customized implant used as a cartilage replacement for early-stage patients; and Epiguide, a drill guide designed to attach to the knee's surface, as well as related surgical tools. The personalization of implants and instruments is based on magnetic resonance imaging (MRI) and enables less invasive treatment. The process of ordering and creation of patient-specific implants and surgical instruments is covered by software suite, microiFidelity, comprising microiClinic, microiDesign and microiManufacture. The main shareholder of the Company is Serendipity Ixora Fund AB.
  • TickerEPIS B
  • ISINSE0003491562
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden
Ole Martin Westgaard ...
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Patrik Ling

Episurf Medical Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks

Episurf Medical (EPISB SS) - Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks excellent. This is important for Episurf Medical, as many doctors as well as payers request long-term follow-up for the implant system to be included in treatment algorithms and reimbursement systems. We reiterate our fair value of SEK1.3–3.9. Long-term follow-up from first 10 patients treated. Episurf Medical reported the lon...

Patrik Ling

Episurf Medical Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks

Episurf Medical (EPISB SS) - Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks excellent. This is important for Episurf Medical, as many doctors as well as payers request long-term follow-up for the implant system to be included in treatment algorithms and reimbursement systems. We reiterate our fair value of SEK1.3–3.9. Long-term follow-up from first 10 patients treated. Episurf Medical reported the lon...

Christer Magnergård ...
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Jon Masdal
  • Jørgen Lian
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolai Farstad Olsen
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Ragnhild Støer
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin
  • Tomi Railo

Northern Lights

Patrik Ling

Episurf Medical Covid-19 hit in Q2, as expected

As we expected, Covid-19 had a clear impact on the number of implant procedures in Q2. As these are elective procedures, they can easily be postponed (as seen in Q2). Despite this, we believe the company had a strong quarter with a good cost control. Over the coming quarters, we believe sales should gradually return. Our new fair value is SEK1.3–3.9 (1.4–4.1).

Patrik Ling

Episurf Medical Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks

Episurf Medical (EPISB SS) - Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks excellent. This is important for Episurf Medical, as many doctors as well as payers request long-term follow-up for the implant system to be included in treatment algorithms and reimbursement systems. We reiterate our fair value of SEK1.3–3.9. Long-term follow-up from first 10 patients treated. Episurf Medical reported the lon...

Patrik Ling

Episurf Medical Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks

Episurf Medical (EPISB SS) - Strong long-term data The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden. We previously saw 24-month data; the patients have now been followed for 75 months and the data still looks excellent. This is important for Episurf Medical, as many doctors as well as payers request long-term follow-up for the implant system to be included in treatment algorithms and reimbursement systems. We reiterate our fair value of SEK1.3–3.9. Long-term follow-up from first 10 patients treated. Episurf Medical reported the lon...

Patrik Ling

Episurf Medical Covid-19 hit in Q2, as expected

As we expected, Covid-19 had a clear impact on the number of implant procedures in Q2. As these are elective procedures, they can easily be postponed (as seen in Q2). Despite this, we believe the company had a strong quarter with a good cost control. Over the coming quarters, we believe sales should gradually return. Our new fair value is SEK1.3–3.9 (1.4–4.1).

Patrik Ling

Episurf Medical Covid-19 to affect procedures

On 24 April Episurf Medical reported solid Q1 earnings, especially bearing in mind that EpiSealer procedures are typically elective and hence among the areas where healthcare organisations globally have lowered activity levels in the wake of Covid-19. This effect should be even more pronounced in Q2. Overall, we believe the company is moving in the right direction and its stable financial situation is a big benefit in the volatile times ahead due to the Covid-19 pandemic. We calculate a fair value of SEK1.4–4.1 (previously SEK1.6–4.3).

Patrik Ling

Episurf Medical Case getting stronger by the day

Yesterday, the company announced that the rights issue announced earlier this year has been completed. In our view, the company is clearly moving in the right direction with the financing being the last piece of the puzzle. In early 2020, it has released strong clinical data supporting the implant system, and now the financial situation is secured until 2022. In total, the company has raised cSEK140m before costs.

Ole Martin Westgaard ...
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Christer Magnergård ...
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Jon Masdal
  • Jørgen Lian
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolai Farstad Olsen
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Ragnhild Støer
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin
  • Tomi Railo

Northern Lights

Christoffer Wang Bjørnsen ...
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Tomi Railo

Northern Lights

Alexander Aukner ...
  • Eivind Sars Veddeng
  • Frank Maaø
  • Håkon Astrup
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Martin Hoang Nguyen
  • Mats Bye
  • Niklas Wetterling
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling

Northern Lights

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch